Home / Themes / MedTech Long '25 : US Drug Dev Outsourcing
MedTech Long '25 : US Drug Dev Outsourcing (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 4 with notes · 4 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis basket benefits from a structural shift toward U.S.-based drug development and biopharma supply chain reshoring, catalyzed by Trump 2.0's trade war posture
Thesis
This basket benefits from a structural shift toward U.S.-based drug development and biopharma supply chain reshoring, catalyzed by Trump 2.0's trade war posture, RFK's anti-China HHS stance, and increasing executive/federal aversion to China-based CRO/CDMO services. Even without the BIOSECURE Act passing, the regulatory and reputational risk of relying on offshore services has spurred U.S.-focused demand, contract wins, and capital investment across the domestic life sciences value chain.
Bull case
BIOSECURE Act failed but reshoring persists: U.S. firms are still redirecting preclinical and manufacturing work away from China to domestic providers like TKNO, NOTV, and FTRE despite the act not passing
Funding inflects off the bottom: Biopharma venture funding and pipeline activity have rebounded in early 2025, driving volume growth for U.S.-centric CRO/CDMOs across diagnostics and early-stage services
AI and organoid initiatives expand TAM: FDA support for AI and lab-based alternatives to animal testing (e.g. CERT, TKNO) is enhancing demand for domestic platforms with data and infrastructure advantages
Bear case
BIOSECURE failure signals policy fade: Without legislation, enforcement risks may ease and large pharma may delay or reverse onshoring investments.
China stimulus and cost arbitrage lure contracts back: Lower-cost Chinese providers may regain market share if political pressure eases or clients seek margin relief.
Capital expenditure slows in downturn: A broader market or biotech correction could delay infrastructure investments and contract volume for U.S.-based vendors.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| BIOSECURE-related policy changes or procurement bans | Event-driven | Identifies changes to contract eligibility or funding restrictions tied to China. | Google_Sheets |
| Domestic biopharma capex and facility investment | Quarterly/Annual | Tracks buildout of U.S. drug manufacturing and development capacity. | Google_Sheets |
| U.S.-only biopharma CRO/CDMO contract flow and RFPs | Quarterly | Measures whether sponsors are selecting domestic over offshore providers. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| CRL_76036562 | literally any day now | 2026-09-02 | 2026-09-16 | Resolution of proposed tax legislation changes in Mauritius is expected. | The outcome of this legislation could impact the company's tax rate and earnings per share, with a lower impact potentially providing upside to current guidance. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| CRL_938f431a | For the third quarter | 2026-07-01 | 2026-09-30 | Charles River Laboratories expects non-GAAP earnings per share in the range of $2.90 to $3.00 for the third quarter of 2026. | This provides specific financial guidance for the upcoming quarter, indicating strong year-over-year EPS growth, which is a key performance indicator for investors. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| CRL_daee1c00 | For the third quarter | 2026-07-01 | 2026-09-30 | Charles River Laboratories expects organic revenue growth of approximately 1% to 3% year-over-year in the third quarter of 2026. | This indicates a continued positive trend in organic revenue growth, driven by improving demand in DSA and a rebound in Biologics Testing, signaling sustained business recovery. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| CRL_d18c27a8 | on September 24 | 2026-09-24 | 2026-09-24 | Charles River Laboratories will host an Investor Day to share information about long-term priorities and financial targets. | This event will provide crucial insights into the company's future strategic direction and financial outlook, potentially impacting long-term investor sentiment and valuation. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| CRL_bc24e2af | largely benefit the fourth quarter | 2026-10-01 | 2026-12-31 | Lower non-human primate (NHP) sourcing costs from the K.F. Cambodia acquisition are expected to largely benefit the Discovery and Safety Assessment (DSA) operating margin. | This will drive significant margin contribution in the DSA segment, improving profitability and competitive advantage due to more reliable NHP supply. | Ticker | 2026-08-05 | earnings_transcript | CRL (ticker) |
| AVTR_5d6352c4 | Tuesday, December 8, in New York City | 2026-12-08 | 2026-12-08 | Avantor to host its Investor Day in New York City. | This event will provide a comprehensive overview of the business strategy, financial objectives, and an opportunity for investors to engage with the leadership team, potentially including updates on portfolio optimization. | Ticker | 2026-07-29 | earnings_transcript | AVTR (ticker) |